Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista argentina de reumatología
versión impresa ISSN 0327-4411versión On-line ISSN 2362-3675
Resumen
QUINTANA, Rosana et al. Lupus in Argentina. . Rev. argent. reumatolg. [online]. 2022, vol.33, n.1, pp.14-25. ISSN 0327-4411. http://dx.doi.org/10.47196/rar.v33i1.602.
Introduction:
lupus is a complex disease and often difficult to approach. Achieving remission is one of the objectives, incorporating therapeutic options.
Objectives:
to describe the characteristics of the patients and the use of belimumab, according to the status of the disease.
Materials and methods:
cross-sectional study. Patients of the RELESSAR registry. Stratification: Remission: SLEDAI=0 and without corticosteroids. Low disease activity SLEDAI> 0 and ≤4 and without corticosteroids and non-optimal control: SLEDAI> 4 and any dose of corticosteroids.
Results:
a total of 1,277 patients were included, 23.4% in remission, 12.6% in low disease activity and 63.8% in non-optimal control. The last group was younger and had a shorter duration of the disease. They had higher activity and chronicity indices and greater use of immunosuppressants. Only 22.3% of the patients with potential criteria for the use of belimumab (activity disease despite standard treatment) were receiving it. The variables associated with hospitalizations were: corticosteroids, cyclophosphamide and higher SLICC. Those associated with severe infection: mycophenolate mofetil, azathioprine, corticosteroids, and higher SLICC.
Conclusions:
the complexity of the management of these patients is reflected, visualizing structural aspects such as inequality. The use of belimumab could be beneficial in selected patients.
Palabras clave : systemic lupus erythematosus; remission; low disease activity; belimumab; real-world data.